logo
Plus   Neg
Share
Email

AstraZeneca: LYNPARZA Shows Progression-free Survival Benefit In Five-year Follow-up Data

AstraZeneca (AZN.L,AZN) and Merck & Co., Inc., announced LYNPARZA showed a long-term progression-free survival benefit versus placebo as a 1st-line maintenance treatment in patients with newly diagnosed, advanced BRCA-mutated ovarian cancer who had a complete or partial response following platinum-based chemotherapy.

The companies said five-year follow-up data from the phase III SOLO-1 trial showed LYNPARZA reduced the risk of disease progression or death by 67% and improved progression-free survival to a median of 56.0 months versus 13.8 months for placebo. At five years, 48.3% of patients treated with LYNPARZA remained free from disease progression versus 20.5% on placebo. The median duration of treatment with LYNPARZA was 24.6 months versus 13.9 months with placebo. The safety profile of LYNPARZA was consistent with previous observations.

The phase III SOLO-1 trial met the primary endpoint of PFS in June 2018, which formed the basis of approvals in the US, the EU, Japan, China, and several other countries.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
CVS Health Corp. is hiring 15,000 employees across the U.S. in the fourth quarter to better equip them to tackle the anticipated rise in COVID-19 and flu incidences during the fall and winter months. This is in addition to the recruitment announced in March to fill 50,000 new full-time, part-time and temporary roles across the country in support of the company's response to the pandemic. Ireland's Data Protection Commissioner or DPC, the European Union's main data privacy regulator, is investigating Facebook over its handling of millions of children's personal data on Instagram, reports said. The agency has started two separate inquiries regarding information that email addresses and phone numbers of users under 18 were made public by the Facebook-owned app. ConocoPhillips (COP) and Concho Resources (CXO) announced Monday that they have entered into a definitive agreement to combine companies in an all-stock transaction valued at $9.7 billion. The transaction creates a company with an approximately $60 billion enterprise value and a combined resource...
Follow RTT